Transformation Clinical Trials

1 recruiting

Transformation Trials at a Glance

10 actively recruiting trials for transformation are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Beijing, Shanghai, and Berlin. Lead sponsors running transformation studies include BeiGene, Beijing University of Chinese Medicine, and Air Force Military Medical University, China.

Browse transformation trials by phase

Treatments under study

About Transformation Clinical Trials

Looking for clinical trials for Transformation? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Transformation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Transformation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1Phase 2

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2

ONO-4538 Study in Patients With Richter's Transformation

Richter's Transformation
Ono Pharmaceutical Co., Ltd.14 enrolled10 locationsNCT06936943
Recruiting
Phase 2

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Chronic Lymphocytic LeukemiaRichter's Transformation
Christine Ryan70 enrolled5 locationsNCT06043674
Recruiting
Not Applicable

Efficacy and Safety of Variceal Embolization Combined With Partial Splenic Artery Embolization for Variceal Bleeding in Cavernous Transformation of Portal Vein.

Cavernous Transformation of Portal VeinGastroesophageal Varices Bleeding
Air Force Military Medical University, China26 enrolled1 locationNCT07310316
Recruiting
Phase 3

Thrombolysis in Factor Xa-inhibitors Trial

StrokeAcute Ischemic StrokeIschemic Stroke+6 more
Guri Hagberg300 enrolled13 locationsNCT06878066
Recruiting
Phase 2

Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation

Richter Transformation
German CLL Study Group83 enrolled11 locationsNCT04271956
Recruiting

Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC

Non-small Cell Lung CancerNeuroendocrine CarcinomaHistology Transformation
Fudan University50 enrolled1 locationNCT06369181
Recruiting
Phase 2

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular CarcinomaBevacizumabAdebrelimab+2 more
The First Affiliated Hospital of Xiamen University71 enrolled1 locationNCT05970666
Recruiting

Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation

Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation
Beijing University of Chinese Medicine2,000 enrolled2 locationsNCT03261934
Recruiting
Phase 2

A phase II study of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as Graft versus Host Disease (GVHD) prophylaxis

Non Hodgkin's Disease in remissionAcute Myeloid Leukaemia in first or second complete remissionacute Lymphoblastic Leukaemia in first or second complete remission+7 more
St Vincent's Hospital Sydney70 enrolled6 locationsACTRN12617000151336